Clinical value of assessing the response to imatinib monitored by interphase FISH and RQ-PCR for BCR-ABL in peripheral blood for long-term survival of chronic phase CML patients: results of the Niigata CML-multi-institutional co-operative clinical study-Reference-Cited by-同舟云学术

Clinical value of assessing the response to imatinib monitored by interphase FISH and RQ-PCR for BCR-ABL in peripheral blood for long-term survival of chronic phase CML patients: results of the Niigata CML-multi-institutional co-operative clinical study

Published:2011-02-05 Issue:3 Volume:93 Page:336-343
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Furukawa Tatsuo,Narita Miwako,Koike Tadashi,Takai Kazue,Nagai Koichi,Kobayashi Masashi,Koyama Satoru,Seki Yoshinobu,Takahashi Hoyu,Fujiwara Masahiro,Kishi Kenji,Nikkuni Koji,Isahai Noriatsu,Higuchi Wataru,Nomoto Nobuhiko,Maruyama Souichi,Masuko Masayoshi,Kuroha Takashi,Abe Takashi,Toba Ken,Takahashi Masuhiro,Aizawa Yoshifusa,Shibata Akira

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/content/pdf/10.1007/s12185-011-0774-2.pdf

Reference26 articles.

1. Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–17.

2. De Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008;26:3358–63.

3. Kantarjian H, O’Brien S, Shan J, Huang X, Garcia-Manero G, Faderl S, et al. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer. 2008;112:837–45.

4. Marin D, Milojkovic D, Olavarria E, Khorashad JS, de Lavallade H, Reid AG, et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood. 2008;112:4437–44.

5. Alvarado Y, Kantarjian H, O’Brien S, Faderl S, Borthakur G, Burger J, et al. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer. 2009;115:3709–18.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New rapid method to detect BCR-ABL fusion genes with multiplex RT-qPCR in one-tube at a time;Leukemia Research;2018-06

2. Assessment of Interleukin 1β Serum Level in Different Responder Groups and Stages of Chronic Myeloid Leukemia Patients on Imatinb Mesylate Therapy;Indian Journal of Hematology and Blood Transfusion;2014-02-07

3. Leucemia mieloide crônica;Revista da Associação Médica Brasileira;2013-05

4. Fluorescence in situ hybridization patterns of BCR/ABL1 fusion in chronic myelogenous leukemia at diagnosis;Indian Journal of Pathology and Microbiology;2012

5. Practical Monitoring of Chronic Myelogenous Leukemia: When to Change Treatment;Journal of the National Comprehensive Cancer Network;2012-01